Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

9

Revenue 2017

Lantus

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lantus was produced by Sanofi.

FDA adcomm split on Sanofi’s type 1 diabetes drug

FDA adcomm split on Sanofi’s type 1 diabetes drug

It is also a key element in Sanofi’s plans to rebuild its diabetes franchise after the loss of patent protection for big-selling basal insulin Lantus (insulin glargine), which has

As France protests, Sanofi takes axe to 670 jobs

As France protests, Sanofi takes axe to 670 jobs The cost-cutting comes as Sanofi is trying to weather the effects of losing patent protection for diabetes blockbuster Lantus (insulin glargine) and build momentum behind new drugs such as atopic

Deal Watch October 2018

agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline The diabetes and cardiovascular division saw revenues decline 15% in the first quarter to 1.08bn, with US sales of Lantus falling 30% in the period.

Dupixent bounce-back helps stem diabetes declines at Sanofi

Dupixent bounce-back helps stem diabetes declines at Sanofi Overall sales at the French pharma group fell almost 6% to 8.3bn ($bn), pegged back by unfavourable exchange rates but also a further 21% drop for Lantus (insulin glargine) due

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics